10x Genomics (TXG) shares outstanding
10x Genomics (TXG) had 124.75M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 3.6% higher than the 120.45M of fiscal 2024. Figures as of 18 Nov 2026, 12:29 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Shares outstanding, fiscal 2025
- 124.75M
- Change on fiscal 2024
- +3.6%
- Growth, 5 years
- +4.3% a year
- Highest on record
- 124.75Mfiscal 2025
- Lowest on record
- 39.09Mfiscal 2019
- Fiscal years on record
- 72019–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
10x Genomics shares outstanding, in more detail
The market data feed counts 121.46M shares outstanding today.
Over the five fiscal years to 2025 the diluted share count grew at a compound 4.3% a year. Across the 7 fiscal years on record (2019–2025), the highest was 124.75M in fiscal 2025 and the lowest 39.09M in fiscal 2019.
Shares outstanding by fiscal year
10x Genomics shares outstanding, year by year
| Fiscal year | Shares outstanding | Change | Year ended |
|---|---|---|---|
| 2025 | 124.75M | 3.6% up | |
| 2024 | 120.45M | 2.8% up | |
| 2023 | 117.17M | 2.9% up | |
| 2022 | 113.86M | 3.2% up | |
| 2021 | 110.35M | 9.1% up | |
| 2020 | 101.15M | 158.8% up | |
| 2019 | 39.09M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed.
How to read it
A falling count means buybacks are giving each remaining share a larger slice of the company; a rising one means owners are being diluted.
Shares outstanding at health care companies of similar size
| Company | Shares outstanding | Fiscal year |
|---|---|---|
| Twist Bioscience TWST | 62.62M | 2026 |
| Protagonist Therapeutics PTGX | 63.57M | 2025 |
| Krystal Biotech KRYS | 29.95M | 2025 |
| 10x Genomics TXG | 124.75M | 2025 |
| Corcept Therapeutics CORT | 119.99M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
10x Genomics, figure by figure
- 10x Genomics market cap
- 10x Genomics revenue
- 10x Genomics earnings
- 10x Genomics earnings per share (EPS)
- 10x Genomics P/E ratio
- 10x Genomics P/S ratio
- 10x Genomics P/B ratio
- 10x Genomics free cash flow
- 10x Genomics operating margin
- 10x Genomics dividend
- 10x Genomics total debt
- 10x Genomics cash on hand
- 10x Genomics total assets
- 10x Genomics return on equity (ROE)
- 10x Genomics return on invested capital (ROIC)
10x Genomics (TXG) overview: price, valuation and scorecardAll health care companies by market value
10x Genomics shares outstanding: questions and answers
How many shares does 10x Genomics have?
10x Genomics (TXG) had 124.75M diluted shares on average in fiscal 2025 (the year ended December 31, 2025). That is 3.6% higher than the 120.45M of fiscal 2024. The market data feed counts 121.46M shares outstanding today.
What is the growth rate of 10x Genomics's diluted share count?
Over the five fiscal years to 2025 the diluted share count grew at a compound 4.3% a year.
What are the highest and lowest diluted share count figures on record for 10x Genomics?
Across the 7 fiscal years on record (2019–2025), the highest was 124.75M in fiscal 2025 and the lowest 39.09M in fiscal 2019.
How is 10x Genomics's diluted share count calculated?
The share count for each fiscal year is the diluted weighted average the company reports with its earnings per share, re-based for later stock splits; the number outstanding today comes from the market data feed. For 10x Genomics it is on record here for 7 fiscal years, 2019 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: shares outstanding
All stocks guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “10x Genomics (TXG) shares outstanding”, data as of 18 November 2026. https://funkfolio.com/stock/TXG/shares-outstanding
Underlying data: the company's filings with the SEC and Yahoo Finance.